DelveInsight’s, “Follicular Lymphoma – Pipeline Insight, 2020,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Follicular Lymphoma Understanding
Follicular Lymphoma: Overview
Lymphoma is a type of blood cancer that develops when white blood cells called lymphocytes grow out of control. Lymphocytes are part of your immune system. They travel around your body in your lymphatic system, and blood, helping you fight infections. There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells).
Lymphomas can be grouped as Hodgkin lymphomas or non-Hodgkin lymphomas, depending on the types of cell they contain. Follicular lymphoma is a common type of slow-growing (low-grade) non-Hodgkin lymphoma that develops from B cells. It is called ‘follicular’ lymphoma because the abnormal B cells usually develop in clumps called ‘follicles’ inside lymph nodes.
Follicular lymphoma is the most common type of low-grade non-Hodgkin lymphoma. In most cases, there is no known cause for follicular lymphoma. Some genetic changes are common in follicular lymphoma, but scientists don’t know what causes them. There is not normally any family history of follicular lymphoma.
Symptoms
Follicular lymphoma is usually very slow-growing so symptoms develop gradually over time. Many people have few symptoms and some have none at all. Sometimes follicular lymphoma is noticed during tests for a different health issue. The most common symptom of follicular lymphoma is a lump or several lumps. These typically develop in neck or just above collar bones but they can develop in other places, such as armpits or groin. Some people have other common symptoms of lymphoma, such as:
• unexplained weight loss
• fevers (temperature above 38ºC)
• drenching sweats, especially at night
• frequent infections, or having difficulty getting over infections
• fatigue (overwhelming tiredness).
Diagnosis
The main way to diagnose follicular lymphoma is to remove a sample of cells from body and look at it under a microscope. This involves a procedure called a biopsy, which is usually done under a local anaesthetic. The biopsy sample is examined by an expert lymphoma pathologist. The pathologist might also test the lymphoma cells for particular proteins and genetic changes.
Treatment
Follicular lymphoma is slow-growing and there is rarely an urgent need for treatment. Some people might not need treatment for many years. Two types of anti-CD20 monoclonal antibodies are used to treat adults with follicular lymphoma and are known as rituximab (Rituxan) and obinutuzumab (Gazyva).
In 1997, the U.S. Food and Drug Administration (FDA) approved rituximab (Rituxan) for the treatment of individuals with follicular lymphoma that did not respond to other treatments (refractory) or returned after treatment (relapsed).
In 2006, rituximab was approved as a first-line therapy for affected individuals. Rituximab can be used alone (as a single agent) as a single-agent therapy. In individuals with bulkier disease or who require a more rapid response (often due to specific symptoms or manifestations), rituximab is used as part of a drug regimen (multiagent chemotherapy) that includes other more traditional chemotherapeutic drugs.
In 2017, the FDA approved obinutuzumab (Gazyva) along with chemotherapy for the treatment of previously untreated individuals with stage II bulky, stage III, or stage IV follicular lymphoma.
There are additional medications that have been approved for the treatment of relapsed or refractory lymphoma. In 2014, the FDA approved the drug, idelalisib (Zydelig), for the treatment of adults with follicular lymphoma who have received at least two other therapies.
The FDA has also approved the drug copanlisib (Aliqopa) for the treatment of adults with relapsed follicular lymphoma who have received at least two other systemic treatments.
Radioimmunotherapy is also used to treat relapsed or refractory follicular lymphoma.
Follicular Lymphoma Emerging Drugs Chapters
This segment of the Follicular Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular Lymphoma Emerging Drugs
• Abexinostat: Xynomic Pharmaceuticals
Abexinostat is the tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins. Abexinostat is being evaluated in a Phase II clinical trial for the treatment of Follicular lymphoma.
• Atezolizumab: Hoffmann-La Roche
Atezolizumab is a humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response.
Further product details are provided in the report……..
Follicular Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Follicular Lymphoma
There are approx. 50+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Dr. Reddy's Laboratories Limited, Novartis, Hoffmann-La Roche, Xynomic Pharmaceuticals, Inc., Celgene, Gilead Sciences, XEME Biopharma , Shanghai YingLi Pharmaceutical Co. Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. etc.
Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Intratumoral
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal antibodies
• Small molecules
• Immunotherapies
• Gene therapies

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Follicular Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular Lymphoma drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Follicular Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular Lymphoma.
• The FDA has granted a fast track designation to abexinostat for the treatment of patients with relapsed or refractory follicular lymphoma in the fourth-line setting.
Follicular Lymphoma Report Insights
• Follicular Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Follicular Lymphoma Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Follicular Lymphoma drugs?
• How many Follicular Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Follicular Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Novartis
• Hoffmann-La Roche
• Xynomic Pharmaceuticals
• Celgene
• Gilead Sciences
• XEME Biopharma
• Shanghai YingLi Pharmaceutical
• Chia Tai Tianqing Pharmaceutical Group
• Dr. Reddy's Laboratories Limited
Key Products
• DRL_RI
• Tisagenlecleucel
• MPDL3280A
• Abexinostat
• Atezolizumab
• Oncoquest-L vaccine
• Linperlisib
• TQ-B3525